Insmed reported $112.5M in Current Liabilities for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acelrx Pharmaceuticals ACRX:US $ 17.07M 1.88M
Alexion Pharmaceuticals ALXN:US $ 1426.2M 198.5M
Alimera Sciences ALIM:US $ 11.4M 1.09M
Arena Pharmaceuticals ARNA:US $ 53.36M 11.48M
Biomarin Pharmaceutical BMRN:US $ 514.9M 71.55M
Cytokinetics CYTK:US $ 80.87M 19.1M
Dynavax Technologies DVAX:US $ 528.93M 324.29M
Flexion Therapeutics FLXN:US $ 43.99M 4.06M
Gilead Sciences GILD:US $ 10245M 31M
Heron Therapeutics HRTX:US $ 72.3M 9.85M
Insmed INSM:US $ 112.5M 12.84M
Mirati Therapeutics MRTX:US $ 122.08M 58.79M
Novartis NVS:US $ 29880M 247M
Regeneron Pharmaceuticals REGN:US $ 3714.8M 17.6M
Sarepta Therapeutics SRPT:US $ 373.44M 51.58M
Seattle Genetics SGEN:US $ 698.43M 264.6M
Ultragenyx Pharmaceutical RARE:US $ 135.93M 8.87M
Vertex Pharmaceuticals VRTX:US $ 1914.26M 77.82M